Date: 2014-06-30
Type of information: Development agreement
Compound: VR506
Company: Vectura (UK) undisclosed US partner (USA)
Therapeutic area: Allergic diseases - Inflammatory diseases - Respiratory diseases
Type agreement: collaboration development licensing
Action mechanism:
Disease: asthma
Details: * On June 30, 2014, Vectura Group announced that it has signed a US collaboration, development and license agreement for VR506, Vectura’s clinical stage asthma monotherapy delivered using Vectura’s proprietary technology. The agreement for VR506 is with Vectura’s existing, undisclosed, US partner for VR315 (a combination therapy for asthma/COPD). Under the terms of this agreement, Vectura’s partner will be responsible for the commercialisation and manufacture of the product together with clinical development. Vectura will provide support for the US development of VR506, for which it will receive an initial payment of $4 million and up to $8 million upon achievement of pre-determined development milestones. Further development fees may be payable to Vectura if the program progresses beyond a pre-defined milestone. In addition, Vectura will receive a royalty from all VR506 US sales.
Financial terms:
Latest news:
